Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab ± tifcemalimab consolidation after chemoradiotherapy in limited-stage small cell lung cancer
jRCT2021240012Phase 3Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Tifcemalimab + toripalimab, Toripalimab + placebo and Double placebo (3 arms). Primary endpoints: Overall survival (Arm A vs Arm C), Overall survival (Arm B vs Arm C) and 2 more. Started Jul 2024; status: recruiting.
02
Drugs
toripalimabtifcemalimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2021240012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240012.